John L. Cleveland, PhD

Where You Are:
John L. Cleveland, PhD

Senior Member

Education And Training
  • PhD, Wayne State University School of Medicine, 1985 - Immunology and Microbiology


  • Seo JW, Ma M, Kwong T, Ju J, Lim SK, Jiang H, Lohman JR, Yang C, Cleveland J, Zazopoulos E, Farnet CM, Shen B. Comparative Characterization of the Lactimidomycin and iso-Migrastatin Biosynthetic Machineries Revealing Unusual Features for Acyltransferase-less Type I Polyketide Synthases and Providing An Opportunity to Engineer New Analogues. Biochemistry-Us. 2014 Nov. Pubmedid: 25405956.
  • Schaub FX, Cleveland JL. Tipping the MYC-MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively blocks MYC-activated genes. EMBO Mol Med. 2014 Nov. Pubmedid: 25368331.
  • Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014 Sep;124(13):2081-2090. Pubmedid: 25143484.
  • Wang H, Yang C, Doherty JR, Roush WR, Cleveland JL, Bannister TD. Synthesis and structure-activity relationships of pteridine Dione and trione monocarboxylate transporter 1 inhibitors. J Med Chem. 2014 Sep;57(17):7317-7324. Pubmedid: 25068893.
  • Amelio AL, Fallahi M, Schaub FX, Zhang M, Lawani MB, Alperstein AS, Southern MR, Young BM, Wu L, Zajac-Kaye M, Kaye FJ, Cleveland JL, Conkright MD. CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement. Proc Natl Acad Sci U S A. 2014 Aug;111(32):E3260-E3268. Pubmedid: 25071166. Pmcid: PMC4136562.
  • Lu Y, Wu Y, Feng X, Shen R, Wang JH, Fallahi M, Li W, Yang C, Hankey W, Zhao W, Ganju RK, Li MO, Cleveland JL, Zou X. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Invest. 2014 Apr;124(4):1672-1684. Pubmedid: 24614102. Pmcid: PMC3973114.
  • Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, Cleveland JL. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 2014 Feb;74(3):908-920. Pubmedid: 24285728. Pmcid: PMC3946415.
  • Doherty JR, Nilsson LM, Kuliyev E, Zhu H, Matthew R, Cleveland JL, Mead PE, Roussel MF. Embryonic Expression and Function of the Xenopus Ink4d Cyclin D-Dependent Kinase Inhibitor. Cell Dev Biol. 2014 Feb;3(1). Pubmedid: 25309971. Pmcid: PMC4192657.
  • Canterbury DP, Scott KE, Kubo O, Jansen R, Cleveland JL, Micalizio GC. Synthesis of C11-Desmethoxy Soraphen A1α: A natural product analog that inhibits acetyl-CoA carboxylase. ACS Med Chem Lett. 2013 Dec;4(12):1244-1248. Pubmedid: 24639892. Pmcid: PMC3951358.
  • Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013 Sep;123(9):3685-3692. Pubmedid: 23999443. Pmcid: PMC3754272.
  • Bibian M, Rahaim RJ, Choi JY, Noguchi Y, Schürer S, Chen W, Nakanishi S, Licht K, Rosenberg LH, Li L, Feng Y, Cameron MD, Duckett DR, Cleveland JL, Roush WR. Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett. 2013 Aug;23(15):4374-4380. Pubmedid: 23787102. Pmcid: PMC3783656.
  • Jeso V, Yang C, Cameron MD, Cleveland JL, Micalizio GC. Synthesis and SAR of Lehualide B: a marine-derived natural product with potent anti-multiple myeloma activity. Acs Chem Biol. 2013 Jun;8(6):1241-1252. Pubmedid: 23547759. Pmcid: PMC3758376.
  • Rounbehler RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, Schaub FX, Sanduja S, Dixon DA, Blackshear PJ, Cleveland JL. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell. 2012 Aug;150(3):563-574. Pubmedid: 22863009. Pmcid: PMC3422762.
  • Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A, Doan HM, Fan J, Cheadle C, Fallahi M, Cleveland JL, Dang CV, Zeller KI. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One. 2012 Feb;6(10):e26057. Pubmedid: 22039435. Pmcid: PMC3198433.
  • Valentin-Vega YA, Maclean KH, Tait-Mulder J, Milasta S, Steeves M, Dorsey FC, Cleveland JL, Green DR, Kastan MB. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012 Feb;119(6):1490-1500. Pubmedid: 22144182. Pmcid: PMC3286212.
  • Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, Zhang J, Iyengar R, Jung CH, Suen DF, Steeves MA, Yang CY, Prater SM, Kim DH, Thompson CB, Youle RJ, Ney PA, Cleveland JL, Kundu M. Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell. 2011 Aug;43(4):572-585. Pubmedid: 21855797. Pmcid: PMC3485687.
  • Ouellette SP, Dorsey FC, Moshiach S, Cleveland JL, Carabeo RA. Chlamydia species-dependent differences in the growth requirement for lysosomes. PLoS One. 2011 Jul;6(3):e16783. Pubmedid: 21408144. Pmcid: PMC3050816.
  • den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010 Sep;116(9):1498-1505. Pubmedid: 20519624. Pmcid: PMC2938839.
  • Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C, Cleveland JL. Myc suppression of Nfkb2 accelerates lymphomagenesis. BMC Cancer. 2010 Aug;10:348. Pubmedid: 20598117. Pmcid: PMC2902445.
  • Steeves MA, Dorsey FC, Cleveland JL. Targeting the autophagy pathway for cancer chemoprevention. Curr Opin Cell Biol. 2010 Apr;22(2):218-225. Pubmedid: 20096553. Pmcid: PMC2854265.
  • Old JB, Kratzat S, Hoellein A, Graf S, Nilsson JA, Nilsson L, Nakayama KI, Peschel C, Cleveland JL, Keller UB. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Mol Cancer Res. 2010 Mar;8(3):353-362. Pubmedid: 20197382. Pmcid: PMC3095030.
  • Dorsey FC, Rose KL, Coenen S, Prater SM, Cavett V, Cleveland JL, Caldwell-Busby J. Mapping the phosphorylation sites of Ulk1. J Proteome Res. 2009 Nov;8(11):5253-5263. Pubmedid: 19807128.
  • Zhang J, Randall MS, Loyd MR, Dorsey FC, Kundu M, Cleveland JL, Ney PA. Mitochondrial clearance is regulated by Atg7-dependent and -independent mechanisms during reticulocyte maturation. Blood. 2009 Jul;114(1):157-164. Pubmedid: 19417210. Pmcid: PMC2710944.
  • Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res. 2009 Jan;69(2):547-553. Pubmedid: 19147568. Pmcid: PMC2749594.
  • Dorsey FC, Steeves MA, Prater SM, Schröter T, Cleveland JL. Monitoring the autophagy pathway in cancer. Methods Enzymol. 2009;453:251-271. Pubmedid: 19216910.
  • Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008 Oct;112(7):2917-2926. Pubmedid: 18641367. Pmcid: PMC2556625.
  • Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, Yue W, Yu J, Zhang L, Onciu M, Sample JT, Cleveland JL, Zambetti GP. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol. 2008 Sep;28(17):5391-5402. Pubmedid: 18573879. Pmcid: PMC2519737.
  • Rodrigues CO, Nerlick ST, White EL, Cleveland JL, King ML. A Myc-Slug (Snail2)/Twist regulatory circuit directs vascular development. Development. 2008 Jun;135(11):1903-1911. Pubmedid: 18469221. Pmcid: PMC2741485.
  • Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA, Marton LJ, Cleveland JL. The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res. 2008 Jun;68(12):4783-4790. Pubmedid: 18559525. Pmcid: PMC2749595.
  • Carew JS, Nawrocki ST, Giles FJ, Cleveland JL. Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics. 2008 Jun;2(2):201-204. Pubmedid: 19707354. Pmcid: PMC2721364.
  • Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest. 2008 Jan;118(1):79-88. Pubmedid: 18097482. Pmcid: PMC2148253.
  • Schweers RL, Zhang J, Randall MS, Loyd MR, Li W, Dorsey FC, Kundu M, Opferman JT, Cleveland JL, Miller JL, Ney PA. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A. 2007 Dec;104(49):19500-19505. Pubmedid: 18048346. Pmcid: PMC2148318.
  • Sanjuan MA, Dillon CP, Tait SW, Moshiach S, Dorsey F, Connell S, Komatsu M, Tanaka K, Cleveland JL, Withoff S, Green DR. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature. 2007 Dec;450(7173):1253-1257. Pubmedid: 18097414.
  • Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy. 2007 Nov;3(5):464-467. Pubmedid: 17495516.
  • Hall MA, Cleveland JL. Clearing the TRAIL for Cancer Therapy. Cancer Cell. 2007 Jul;12(1):4-6. Pubmedid: 17613431.
  • Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res. 2007 Jul;67(14):6987-6994. Pubmedid: 17638911.
  • Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007 Jul;110(1):313-322. Pubmedid: 17363733. Pmcid: PMC1896119.
  • Maclean KH, Kastan MB, Cleveland JL. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol Cancer Res. 2007 Jul;5(7):705-711. Pubmedid: 17634425.
  • Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveldz GC. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol. 2007 May;177(3):563. Pubmedid: 17485494. Pmcid: PMC2064814.
  • Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, Chung L, Yang C, Spruck C, Boyd K, Reed SI, Cleveland JL. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. Embo J. 2007 May;26(10):2562-2574. Pubmedid: 17464290. Pmcid: PMC1868903.
  • Nilsson LM, Keller UB, Yang C, Nilsson JA, Cleveland JL, Roussel MF. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis. Oncogene. 2007 May;26(20):2833-2839. Pubmedid: 17099725.
  • Wen R, Chen Y, Bai L, Fu G, Schuman J, Dai X, Zeng H, Yang C, Stephan RP, Cleveland JL, Wang D. Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis. Mol Cell Biol. 2006 Dec;26(24):9364-9376. Pubmedid: 17030619. Pmcid: PMC1698523.
  • Moreno-Miralles I, Pan L, Keates-Baleeiro J, Durst-Goodwin K, Yang C, Kim HG, Thompson MA, Klug CA, Cleveland JL, Hiebert SW. The inv(16) cooperates with ARF haploinsufficiency to induce acute myeloid leukemia. J Biol Chem. 2005 Dec;280(48):40097-40103. Pubmedid: 16199529.
  • Kasper LH, Boussouar F, Boyd K, Xu W, Biesen M, Rehg J, Baudino TA, Cleveland JL, Brindle PK. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. Embo J. 2005 Nov;24(22):3846-3858. Pubmedid: 16237459. Pmcid: PMC1283945.
  • Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol. 2005 Sep;170(6):903-912. Pubmedid: 16157701. Pmcid: PMC2171446.
  • Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene. 2005 Sep;24(41):6231-6240. Pubmedid: 15940251.
  • Bois PR, Brochard VF, Salin-Cantegrel AV, Cleveland JL, Grosveld GC. FoxO1a-cyclic GMP-dependent kinase I interactions orchestrate myoblast fusion. Mol Cell Biol. 2005 Sep;25(17):7645-7656. Pubmedid: 16107711. Pmcid: PMC1190306.
  • Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005 Aug;436(7052):807-811. Pubmedid: 16094360.
  • Ulett GC, Maclean KH, Nekkalapu S, Cleveland JL, Adderson EE. Mechanisms of group B streptococcal-induced apoptosis of murine macrophages. J Immunol. 2005 Aug;175(4):2555-2562. Pubmedid: 16081829.
  • Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell. 2005 May;7(5):433-444. Pubmedid: 15894264.
  • Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S, Ozbek U, Boyd K, Cleveland JL, Grosveld GC. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol Cell Biol. 2005 Mar;25(6):2395-2405. Pubmedid: 15743832. Pmcid: PMC1061619.
  • Guo Y, Cleveland JL, O'Brien TG. Haploinsufficiency for odc modifies mouse skin tumor susceptibility. Cancer Res. 2005 Feb;65(4):1146-1149. Pubmedid: 15734996.
  • Nilsson JA, Nilsson LM, Keller U, Yokota Y, Boyd K, Cleveland JL. Id2 is dispensable for myc-induced lymphomagenesis. Cancer Res. 2004 Oct;64(20):7296-7301. Pubmedid: 15492249.
  • Cleveland JL, Sherr CJ. Antagonism of Myc functions by Arf. Cancer Cell. 2004 Oct;6(4):309-311. Pubmedid: 15488753.
  • Nilsson JA, Cleveland JL. Mnt: master regulator of the Max network. Cell Cycle. 2004 May;3(5):588-590. Pubmedid: 15107624.
  • Nilsson JA, Maclean KH, Keller UB, Pendeville H, Baudino TA, Cleveland JL. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol. 2004 Feb;24(4):1560-1569. Pubmedid: 14749372. Pmcid: PMC344188.
  • Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A. 2003 Dec;100(26):15930-15935. Pubmedid: 14665695. Pmcid: PMC307670.
  • Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003 Dec;22(56):9007-9021. Pubmedid: 14663479.
  • Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003 Oct;4(4):321-328. Pubmedid: 14585359.
  • Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol. 2003 Oct;23(20):7256-7270. Pubmedid: 14517295. Pmcid: PMC230315.
  • Cleveland JL. A new piece of the ALS puzzle. Nat Genetics. 2003 Aug;34(4):357-358. Pubmedid: 12923539.
  • Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF, Cleveland JL. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell. 2003 Apr;11(4):905-914. Pubmedid: 12718877.
  • Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. Embo J. 2003 Mar;22(6):1442-1450. Pubmedid: 12628936. Pmcid: PMC151074.
  • Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN, Cleveland JL. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Gene Dev. 2002 Oct;16(19):2530-2543. Pubmedid: 12368264. Pmcid: PMC187450.
  • Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, Lothstein L. Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther. 2002 May;1(7):469-481. Pubmedid: 12479265.
  • Eischen CM, Rehg JE, Korsmeyer SJ, Cleveland JL. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice. Cancer Res. 2002 Apr;62(7):2184-2191. Pubmedid: 11929842.
  • Fee BE, Doyle CA, Cleveland JL. A novel Eyes Absent 2 protein is expressed in the human eye. Gene. 2002 Feb;285(1-2):221-228. Pubmedid: 12039049.
  • Clark SW, Fee BE, Cleveland JL. Misexpression of the eyes absent family triggers the apoptotic program. J Biol Chem. 2002 Feb;277(5):3560-3567. Pubmedid: 11700312.
  • Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR. Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest. 2002 Jan;109(1):19-27. Pubmedid: 11781347. Pmcid: PMC150815.
  • Maclean KH, Cleveland JL, Porter JB. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes. Blood. 2001 Dec;98(13):3831-3839. Pubmedid: 11739193.
  • Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol. 2001 Nov;21(22):7653-7662. Pubmedid: 11604501. Pmcid: PMC99936.
  • Braun JS, Novak R, Murray PJ, Eischen CM, Susin SA, Kroemer G, Halle A, Weber JR, Tuomanen EI, Cleveland JL. Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J Infect Dis. 2001 Nov;184(10):1300-1309. Pubmedid: 11679919.
  • Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, Cleveland JL. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene. 2001 Oct;20(48):6983-6993. Pubmedid: 11704823.
  • Pestina TI, Cleveland JL, Yang C, Zambetti GP, Jackson CW. Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood. 2001 Oct;98(7):2084-2090. Pubmedid: 11567994.
  • Pendeville H, Carpino N, Marine JC, Takahashi Y, Muller M, Martial JA, Cleveland JL. The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol Cell Biol. 2001 Oct;21(19):6549-6558. Pubmedid: 11533243. Pmcid: PMC99801.
  • Magnet KJ, Orr MS, Cleveland JL, Rodriguez-Galindo C, Yang H, Yang C, Di YM, Jain PT, Gewirtz DA. Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells. Biochem Pharmacol. 2001 Sep;62(5):593-602. Pubmedid: 11585056.
  • Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem. 2001 Aug;276(32):29994-30001. Pubmedid: 11402027.
  • Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001 Aug;21(15):5063-5070. Pubmedid: 11438662. Pmcid: PMC87232.
  • Rodriguez-Galindo C, Poquette CA, Daw NC, Tan M, Meyer WH, Cleveland JL. Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. Med Pediatr Oncol. 2001 Jun;36(6):605-611. Pubmedid: 11344491.
  • Baudino TA, Cleveland JL. The Max network gone mad. Mol Cell Biol. 2001 Feb;21(3):691-702. Pubmedid: 11154257. Pmcid: PMC86661.
  • Nip J, Strom DK, Eischen CM, Cleveland JL, Zambetti GP, Hiebert SW. E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene. 2001 Feb;20(8):910-920. Pubmedid: 11314026.
  • Wen R, Wang D, McKay C, Bunting KD, Marine JC, Vanin EF, Zambetti GP, Korsmeyer SJ, Ihle JN, Cleveland JL. Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. Mol Cell Biol. 2001 Jan;21(2):678-689. Pubmedid: 11134353. Pmcid: PMC86650.
  • Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma. Curr Top Microbiol. 2001;258:153-160. Pubmedid: 11443860.
  • Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Gene Dev. 2000 Dec;14(24):3102-3114. Pubmedid: 11124803. Pmcid: PMC317128.
  • Ruf IK, Rhyne PW, Yang C, Cleveland JL, Sample JT. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol. 2000 Nov;74(21):10223-10228. Pubmedid: 11024153. Pmcid: PMC102063.
  • Cleveland JL, Kastan MB. Cancer. A radical approach to treatment. Nature. 2000 Sep;407(6802):309-311. Pubmedid: 11014172.
  • Inoue K, Wen R, Rehg JE, Adachi M, Cleveland JL, Roussel MF, Sherr CJ. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Gene Dev. 2000 Jul;14(14):1797-1809. Pubmedid: 10898794. Pmcid: PMC316790.
  • Wang D, Feng J, Wen R, Marine JC, Sangster MY, Parganas E, Hoffmeyer A, Jackson CW, Cleveland JL, Murray PJ, Ihle JN. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity. 2000 Jul;13(1):25-35. Pubmedid: 10933392.
  • Dai H, Kramer DL, Yang C, Murti KG, Porter CW, Cleveland JL. The polyamine oxidase inhibitor MDL-72,527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects. Cancer Res. 1999 Oct;59(19):4944-4954. Pubmedid: 10519408.
  • Braun JS, Tuomanen EI, Cleveland JL. Neuroprotection by caspase inhibitors. Expert Opin Inv Drug. 1999 Oct;8(10):1599-1610. Pubmedid: 11139813.
  • Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Gene Dev. 1999 Oct;13(20):2658-2669. Pubmedid: 10541552. Pmcid: PMC317106.
  • Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol. 1999 Mar;19(3):1651-1660. Pubmedid: 10022853. Pmcid: PMC83959.
  • Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med. 1999 Mar;5(3):298-302. Pubmedid: 10086385.
  • Florio M, Hernandez MC, Yang H, Shu HK, Cleveland JL, Israel MA. Id2 promotes apoptosis by a novel mechanism independent of dimerization to basic helix-loop-helix factors. Mol Cell Biol. 1998 Sep;18(9):5435-5444. Pubmedid: 9710627. Pmcid: PMC109128.
  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Gene Dev. 1998 Aug;12(15):2424-2433. Pubmedid: 9694806. Pmcid: PMC317045.
  • Packham G, White EL, Eischen CM, Yang H, Parganas E, Ihle JN, Grillot DA, Zambetti GP, Nuñez G, Cleveland JL. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Gene Dev. 1998 Aug;12(16):2475-2487. Pubmedid: 9716401. Pmcid: PMC317092.
  • Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol. 1998 Jul;18(7):3735-3743. Pubmedid: 9632756. Pmcid: PMC108956.
  • Quelle FW, Wang J, Feng J, Wang D, Cleveland JL, Ihle JN, Zambetti GP. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Gene Dev. 1998 Apr;12(8):1099-1107. Pubmedid: 9553040. Pmcid: PMC316716.
  • Strom DK, Cleveland JL, Chellappan S, Nip J, Hiebert SW. E2F-1 and E2F-3 are functionally distinct in their ability to promote myeloid cell cycle progression and block granulocyte differentiation. Cell Growth Differ. 1998 Jan;9(1):59-69. Pubmedid: 9438389.
  • Packham G, Brimmell M, Cleveland JL. Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J. 1997 Dec;328 ( Pt 3):807-813. Pubmedid: 9396724. Pmcid: PMC1218990.
  • Brewer JW, Cleveland JL, Hendershot LM. A pathway distinct from the mammalian unfolded protein response regulates expression of endoplasmic reticulum chaperones in non-stressed cells. Embo J. 1997 Dec;16(23):7207-7216. Pubmedid: 9384597. Pmcid: PMC1170321.
  • Zhan Y, Cleveland JL, Stevens JL. A role for c-myc in chemically induced renal-cell death. Mol Cell Biol. 1997 Nov;17(11):6755-6764. Pubmedid: 9343440. Pmcid: PMC232530.
  • Packham G, Cleveland JL. Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways. Oncogene. 1997 Sep;15(10):1219-1232. Pubmedid: 9294616.
  • Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol. 1997 Mar;17(3):1049-1056. Pubmedid: 9032231. Pmcid: PMC231829.
  • Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. Proc Natl Acad Sci U S A. 1997 Mar;94(6):2609-2614. Pubmedid: 9122243. Pmcid: PMC20136.
  • Packham G, Lahti JM, Fee BE, Gawn JM, Coustan-Smith E, Campana D, Douglas I, Kidd VJ, Ghosh S, Cleveland JL. Fas activates NF-kappaB and induces apoptosis in T-cell lines by signaling pathways distinct from those induced by TNF-alpha. Cell Death Differ. 1997 Feb;4(2):130-139. Pubmedid: 16465219.
  • Packham G, Porter CW, Cleveland JL. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene. 1996 Aug;13(3):461-469. Pubmedid: 8760287.
  • Packham G, Ashmun RA, Cleveland JL. Cytokines suppress apoptosis independent of increases in reactive oxygen levels. J Immunol. 1996 Apr;156(8):2792-2800. Pubmedid: 8609398.
  • Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, Cleveland JL. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol. 1995 Dec;15(12):6864-6874. Pubmedid: 8524253. Pmcid: PMC230941.
  • Ofir R, Novick I, Krup M, Cleveland JL, Ihle JN, Weinstein Y. Structural and functional analysis of the promoter of the murine V gamma 1.1 T cell receptor gene. Eur J Immunol. 1995 Nov;25(11):3070-3078. Pubmedid: 7489745.
  • Katzav S, Packham G, Sutherland M, Aroca P, Santos E, Cleveland JL. Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function. Oncogene. 1995 Sep;11(6):1079-1088. Pubmedid: 7566967.
  • Packham G, Cleveland JL. c-Myc and apoptosis. Biochim Biophys Acta. 1995 Jul;1242(1):11-28. Pubmedid: 7626652.
  • Matsugi T, Kreider BL, Delwel R, Cleveland JL, Askew DS, Ihle JN. The Evi-1 zinc finger myeloid transforming protein binds to genomic fragments containing (GATA)n sequences. Oncogene. 1995 Jul;11(1):191-198. Pubmedid: 7624127.
  • Quelle FW, Shimoda K, Thierfelder W, Fischer C, Kim A, Ruben SM, Cleveland JL, Pierce JH, Keegan AD, Nelms K. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol. 1995 Jun;15(6):3336-3343. Pubmedid: 7760829. Pmcid: PMC230567.
  • Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell. 1995 May;81(4):479-482. Pubmedid: 7758103.
  • Packham G, Cleveland JL. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr Top Microbiol. 1995;194:283-290. Pubmedid: 7895500.
  • Conley ME, Fitch-Hilgenberg ME, Cleveland JL, Parolini O, Rohrer J. Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase. Hum Mol Genet. 1994 Oct;3(10):1751-1756. Pubmedid: 7849697.
  • Packham G, Cleveland JL. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol. 1994 Sep;14(9):5741-5747. Pubmedid: 8065308. Pmcid: PMC359099.
  • Cleveland JL, Troppmair J, Packham G, Askew DS, Lloyd P, González-Garcia M, Nuñez G, Ihle JN, Rapp UR. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene. 1994 Aug;9(8):2217-2226. Pubmedid: 8036007.
  • Roussel MF, Davis JN, Cleveland JL, Ghysdael J, Hiebert SW. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene. 1994 Feb;9(2):405-415. Pubmedid: 8290253.
  • Packham G, Bello-Fernandez C, Cleveland JL. Position and orientation independent transactivation by c-Myc. Cell Mol Biol Res. 1994;40(7-8):699-706. Pubmedid: 7787888.
  • Askew DS, Ihle JN, Cleveland JL. Activation of apoptosis associated with enforced myc expression in myeloid progenitor cells is dominant to the suppression of apoptosis by interleukin-3 or erythropoietin. Blood. 1993 Oct;82(7):2079-2087. Pubmedid: 8400257.
  • Armstrong E, Korhonen J, Silvennoinen O, Cleveland JL, Lieberman MA, Alitalo R. Expression of tie receptor tyrosine kinase in leukemia cell lines. Leukemia. 1993 Oct;7(10):1585-1591. Pubmedid: 8412320.
  • Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci U S A. 1993 Sep;90(18):8429-8433. Pubmedid: 8378315. Pmcid: PMC47370.
  • Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A. 1993 Aug;90(16):7804-7808. Pubmedid: 8356088. Pmcid: PMC47231.
  • Miura O, Cleveland JL, Ihle JN. Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol Cell Biol. 1993 Mar;13(3):1788-1795. Pubmedid: 8382775. Pmcid: PMC359491.
  • Reynolds AB, Herbert L, Cleveland JL, Berg ST, Gaut JR. p120, a novel substrate of protein tyrosine kinase receptors and of p60v-src, is related to cadherin-binding factors beta-catenin, plakoglobin and armadillo. Oncogene. 1992 Dec;7(12):2439-2445. Pubmedid: 1334250.
  • Okuda T, Cleveland JL, Downing JR. PCTAIRE-1 and PCTAIRE-3, two members of a novel cdc2/CDC28-related protein kinase gene family. Oncogene. 1992 Nov;7(11):2249-2258. Pubmedid: 1437147.
  • Duyao MP, Kessler DJ, Spicer DB, Bartholomew C, Cleveland JL, Siekevitz M, Sonenshein GE. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J Biol Chem. 1992 Aug;267(23):16288-16291. Pubmedid: 1644814.
  • Rock CO, Cleveland JL, Jackowski S. Macrophage growth arrest by cyclic AMP defines a distinct checkpoint in the mid-G1 stage of the cell cycle and overrides constitutive c-myc expression. Mol Cell Biol. 1992 May;12(5):2351-2358. Pubmedid: 1373814. Pmcid: PMC364407.
  • Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol. 1992 Feb;12(2):836-846. Pubmedid: 1732748. Pmcid: PMC364317.
  • Troppmair J, Cleveland JL, Askew DS, Rapp UR. v-Raf/v-Myc synergism in abrogation of IL-3 dependence: v-Raf suppresses apoptosis. Curr Top Microbiol. 1992;182:453-460. Pubmedid: 1490385.
  • Bello-Fernandez C, Cleveland JL. c-myc transactivates the ornithine decarboxylase gene. Curr Top Microbiol. 1992;182:445-452. Pubmedid: 1490383.
  • Yi T, Cleveland JL, Ihle JN. Identification of novel protein tyrosine phosphatases of hematopoietic cells by polymerase chain reaction amplification. Blood. 1991 Nov;78(9):2222-2228. Pubmedid: 1932742.
  • Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 1991 Oct;6(10):1915-1922. Pubmedid: 1923514.
  • Roussel MF, Cleveland JL, Shurtleff SA, Sherr CJ. Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature. 1991 Sep;353(6342):361-363. Pubmedid: 1833648.
  • Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol. 1991 Apr;11(4):1912-1920. Pubmedid: 2005887. Pmcid: PMC359873.
  • Beck TW, Brennscheidt U, Sithanandam G, Cleveland J, Rapp UR. Molecular organization of the human Raf-1 promoter region. Mol Cell Biol. 1990 Jul;10(7):3325-3333. Pubmedid: 1694010. Pmcid: PMC360752.
  • Principato M, Cleveland JL, Rapp UR, Holmes KL, Pierce JH, Morse HC, Klinken SP. Transformation of murine bone marrow cells with combined v-raf-v-myc oncogenes yields clonally related mature B cells and macrophages. Mol Cell Biol. 1990 Jul;10(7):3562-3568. Pubmedid: 2162474. Pmcid: PMC360791.
  • Heidecker G, Huleihel M, Cleveland JL, Kolch W, Beck TW, Lloyd P, Pawson T, Rapp UR. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol. 1990 Jun;10(6):2503-2512. Pubmedid: 2188091. Pmcid: PMC360607.
  • Storm SM, Cleveland JL, Rapp UR. Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene. 1990 Mar;5(3):345-351. Pubmedid: 1690378.
  • Cleveland JL, Dean M, Rosenberg N, Wang JY, Rapp UR. Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol Cell Biol. 1989 Dec;9(12):5685-5695. Pubmedid: 2555703. Pmcid: PMC363740.
  • Weinstein Y, Morishita K, Cleveland JL, Ihle JN. Interleukin 3 (IL-3) induces transcription from nonrearranged T cell receptor gamma loci in IL-3-dependent cell lines. J Exp Med. 1989 Jun;169(6):2059-2071. Pubmedid: 2543731. Pmcid: PMC2189342.
  • Greil K, Gattringer C, Fasching B, Cleveland J, Thaler J, Radaskiewicz T, Gastl G, Huber C, Rapp U, Huber H. abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status. Int J Cancer. 1988 Oct;42(4):529-538. Pubmedid: 3049401.
  • Horton WE, Cleveland J, Rapp U, Nemuth G, Bolander M, Doege K, Yamada Y, Hassell JR. An established rat cell line expressing chondrocyte properties. Exp Cell Res. 1988 Oct;178(2):457-468. Pubmedid: 3049123.
  • Farrar WL, Vinocour M, Cleveland JL, Harel-Bellan A. Regulation of ornithine decarboxylase activity by IL-2 and cyclic AMP. J Immunol. 1988 Aug;141(3):967-971. Pubmedid: 2840461.
  • Cleveland JL, Huleihel M, Bressler P, Siebenlist U, Akiyama L, Eisenman RN, Rapp UR. Negative regulation of c-myc transcription involves myc family proteins. Oncogene Res. 1988;3(4):357-375. Pubmedid: 2976141.
  • Rapp UR, Heidecker G, Huleihel M, Cleveland JL, Choi WC, Pawson T, Ihle JN, Anderson WB. raf family serine/threonine protein kinases in mitogen signal transduction. Cold Spring Harb Symp Quant Biol. 1988;53 Pt 1:173-184. Pubmedid: 2978288.
  • Dean M, Cleveland J, Kim HY, Campisi J, Levine RA, Ihle JN, Rapp U. Deregulation of the c-myc and N-myc genes in transformed cells. Curr Top Microbiol. 1988;141:216-222. Pubmedid: 3215051.
  • Cleveland JL, Dean M, Wang JY, Hedge AM, Ihle JN, Rapp UR. Abrogation of IL-3 dependence of myeloid FDC-P1 cells by tyrosine kinase oncogenes is associated with induction of c-myc. Curr Top Microbiol. 1988;141:300-309. Pubmedid: 3265092.
  • Troppmair J, Huleihel M, Cleveland J, Mushinski JF, Kurie J, Morse HC, Wax JS, Potter M, Rapp UR. Plasmacytoma induction by J series of v-myc recombinant retroviruses: evidence for the requirement of two (raf and myc) oncogenes for transformation. Curr Top Microbiol. 1988;141:110-114. Pubmedid: 3215044.
  • Principato M, Klinken SP, Cleveland JL, Rapp UR, Holmes KL, Pierce JH, Morse HC. In vitro transformation of murine bone marrow cells with a v-raf/v-myc retrovirus yields clonally related mature B cells and macrophages. Curr Top Microbiol. 1988;141:31-41. Pubmedid: 3265093.
  • Farrar WL, Evans SW, Rapp UR, Cleveland JL. Effects of anti-proliferative cyclic AMP on interleukin 2-stimulated gene expression. J Immunol. 1987 Sep;139(6):2075-2080. Pubmedid: 3040863.
  • Dean M, Cleveland JL, Rapp UR, Ihle JN. Role of myc in the abrogation of IL3 dependence of myeloid FDC-P1 cells. Oncogene Res. 1987 Aug;1(3):279-296. Pubmedid: 2453016.
  • Weinstein Y, Cleveland JL, Askew DS, Rapp UR, Ihle JN. Insertion and truncation of c-myb by murine leukemia virus in a myeloid cell line derived from cultures of normal hematopoietic cells. J Virol. 1987 Jul;61(7):2339-2343. Pubmedid: 2884332. Pmcid: PMC283705.
  • Cleveland JL, Rapp UR, Farrar WL. Role of c-myc and other genes in interleukin 2 regulated CT6 T lymphocytes and their malignant variants. J Immunol. 1987 May;138(10):3495-3504. Pubmedid: 3106484.
  • Ihle JN, Weinstein Y, Rapp UR, Cleveland JL, Reddy EP. Mechanisms in interleukin 3 regulated growth and differentiation. Adv Exp Med Biol. 1987;213:149-162. Pubmedid: 3498294.
  • Rapp UR, Storm SM, Cleveland JL. Oncogenes: clinical relevance. Haematol Blood Transfus. 1987;31:450-459. Pubmedid: 3327780.
  • Morse HC, Hartley JW, Fredrickson TN, Yetter RA, Majumdar C, Cleveland JL, Rapp UR. Recombinant murine retroviruses containing avian v-myc induce a wide spectrum of neoplasms in newborn mice. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6868-6872. Pubmedid: 3018749. Pmcid: PMC386611.
  • Farrar WL, Cleveland JL, Beckner SK, Bonvini E, Evans SW. Biochemical and molecular events associated with interleukin 2 regulation of lymphocyte proliferation. Immunol Rev. 1986 Aug;92:49-65. Pubmedid: 3091482.
  • Huleihel M, Goldsborough M, Cleveland J, Gunnell M, Bonner T, Rapp UR. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol Cell Biol. 1986 Jul;6(7):2655-2662. Pubmedid: 3491291. Pmcid: PMC367822.
  • Huebner K, ar-Rushdi A, Griffin CA, Isobe M, Kozak C, Emanuel BS, Nagarajan L, Cleveland JL, Bonner TI, Goldsborough MD. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. Proc Natl Acad Sci U S A. 1986 Jun;83(11):3934-3938. Pubmedid: 3520560. Pmcid: PMC323639.
  • Rapp UR, Cleveland JL, Storm SM, Beck TW, Huleihel M. Transformation by raf and myc oncogenes. Princess Takamatsu Symp. 1986;17:55-74. Pubmedid: 3332021.
  • Morse HC, Hartley JW, Fredrickson TN, Yetter RA, Cleveland JL, Majumdar C, Rapp UR. Tumors of newborn NFS/N mice infected with murine retroviruses containing avian v-myc. Curr Top Microbiol. 1986;132:17-22. Pubmedid: 3024912.
  • Cleveland JL, Jansen HW, Bister K, Fredrickson TN, Morse HC, Ihle JN, Rapp UR. Interaction between Raf and Myc oncogenes in transformation in vivo and in vitro. J Cell Biochem. 1986;30(3):195-218. Pubmedid: 3084503.
  • Cleveland JL, Weinstein Y, Ihle JN, Askew DS, Rapp UR. Transformation and insertional mutagenesis in vitro of primary hematopoietic stem cell cultures. Curr Top Microbiol. 1986;132:44-54. Pubmedid: 3024923.
  • Rapp UR, Cleveland JL, Fredrickson TN, Holmes KL, Morse HC, Jansen HW, Patschinsky T, Bister K. Rapid induction of hemopoietic neoplasms in newborn mice by a raf(mil)/myc recombinant murine retrovirus. J Virol. 1985 Jul;55(1):23-33. Pubmedid: 4009794. Pmcid: PMC254893.
  • Weinstein Y, Askew DS, Miura O, Cleveland JL, Ihle JN. Regulation of T cell receptor gamma gene expression by cytokines in murine hematopoietic cells. Eur Cytokine Netw. 6(2):97-102. Pubmedid: 7578993.
  • Rapp UR, Cleveland JL, Brightman K, Scott A, Ihle JN. Abrogation of IL-3 and IL-2 dependence by recombinant murine retroviruses expressing v-myc oncogenes. Nature. 317(6036):434-438. Pubmedid: 3930972.
  • Blasi E, Mathieson BJ, Varesio L, Cleveland JL, Borchert PA, Rapp UR. Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus. Nature. 318(6047):667-670. Pubmedid: 4079980.
  • Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin LS, Choi A, Chu CT, Chung J, Clarke PG, Clark RS, Clarke SG, Clavé C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, Difiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dröge W, Dron M, Dunn WA, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen EL, Fésüs L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao FB, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, González-Estévez C, Gorski S, Gottlieb RA, Häussinger D, He YW, Heidenreich K, Hill JA, Høyer-Hansen M, Hu X, Huang WP, Iwasaki A, Jäättelä M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JA, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kovács AL, Kroemer G, Kuan CY, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei HY, Lenardo MJ, Levine B, Lieberman A, Lim KL, Lin FC, Liou W, Liu LF, Lopez-Berestein G, López-Otín C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Meléndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska ...
  • Maclean K, Yang H, Cleveland JL. Serum suppresses myeloid progenitor apoptosis by regulating iron homeostasis. J Cell Biochem. 82(1):171-186. Pubmedid: 11400174.
  • Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 2002 Jul;8(7):743-750. Pubmedid: 12091906.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions